Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 4 1Phase 2 1

Status

Completed 3Withdrawn 1Unknown 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 8Lymphoid 7Breast 7Tumor-Agnostic 5Plasma cell 5Myeloid 5Gynecologic 5CNS 5Gastrointestinal 4Dermatologic 4Sarcoma 2Genitourinary 2Other solid neoplasm 1Other neoplasm 1Head & Neck 1

Conditions

Neoplasms 5

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 48Radiotherapy 39Magnetic Resonance Spectroscopy 35pembrolizumab 31Gemcitabine 30Bevacizumab 30Nivolumab 29Carboplatin 29Radiosurgery 27Standard of Care 26Oxaliplatin 26Capecitabine 25Paclitaxel 24Interviews as Topic 24Cisplatin 24Fluorouracil 23Erlotinib Hydrochloride 22Everolimus 19Irinotecan 18Trastuzumab 17Methods 17Exercise 17Docetaxel 17Biopsy 17Cyclophosphamide 16Educational Status 15Sorafenib 14Ipilimumab 14Fluorodeoxyglucose F18 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Ondansetron × Tumor-Agnostic × Clear all
NCT03578081 2025-04-06

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

Alliance for Clinical Trials in Oncology

Phase 3 Completed
690 enrolled 17 charts
Tumor-Agnostic

Neoplasms

NCT04508400 2024-01-09

Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients

Sun Yat-sen University

Phase 2 Completed
108 enrolled
Tumor-Agnostic

Neoplasms

NCT05872893 2023-07-21

Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone

Immune Oncology Research Institute

Phase 3 Unknown
40 enrolled
Tumor-Agnostic

Neoplasms

NCT01640340 2013-11-07

Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)

Ohio State University Comprehensive Cancer Center

Phase NA Completed
40 enrolled 12 charts
Tumor-Agnostic

Neoplasms

NCT01896440 2013-10-08

Heart Safety Study of Ondansetron in Children Receiving Chemotherapy

University of Oklahoma

Phase 4 Withdrawn
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡